Pharming provides update on outstanding shares
(Thomson Reuters ONE) -
Leiden, The Netherlands, June 2, 2010. Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announced that its current number of
outstanding shares has increased from 154,501,037 at March 31, 2010 to
277,206,421 as per today.
The increase reflects 100,000,000 shares issued in relation to an equity
fundraising of ?12.0 million ("the Offering") as announced on May 28, 2010, as
well as an aggregate number of 22,705,384 shares issued in relation to various
conversions of bonds issued in January 2010 and the first quarter interest
payment of these bonds. As a result of these conversions, the original nominal
value of the bonds issued in January 2010 in the amount of ?7.5 million has
decreased to ?3.0 million today.
About the Offering
On May 27, 2010, Pharming announced its intention to raise ?12 million by means
of a private placement . On May 28, 2010, the details of the Offering, 100
million shares ("the Offer Shares") at an issue price of ?0.12 per Offer Share,
were announced. The price of the Offer Shares was determined based on an
extensive period of road shows and marketing research with new institutional
investors and existing shareholders. The Offering has initially been pre-offered
as a private placement with existing and new institutional investors, leading to
pre-commitments for an aggregate amount of ?5.5 million. Following the approval
of a Prospectus, the remainder of the Offering was launched on May 28, 2010 at
8.00 am CET. Non-institutional investors were welcome to participate as well at
a minimal investment of ?50,000. Within two hours, the order book for the
Offering was oversubscribed and closed. Subscribing to the Offering is thus no
longer possible.
Pharming was advised in the Offering by Kempen & Co NV and Petercam Bank NV.
Selling agents were Roth Capital, Heartstream Corporate Finance BV, First Berlin
and Montrose Capital.
All documents relating to the Offering can be found on Pharming's website:
www.pharming.com
/> Equity Fundraising May 2010.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, ageing diseases, specialty products for surgical indications, and
nutritional products. Pharming's lead product Rhucin® for acute attacks of
Hereditary Angioedema has passed clinical development stage and the Market
Authorization Application is under review with the European Medicines Agency.
Prodarsan® - a product under development by Pharming's subsidiary DNage - is in
early stage clinical development for Cockayne Syndrome and lactoferrin for use
in food products. The advanced technologies of the Company include innovative
platforms for the production of protein therapeutics, technology and processes
for the purification and formulation of these products, as well as technology in
the field of DNA repair (via DNage). Recently the partial spin- out of DNage was
initiated. Additional information is available on the Pharming website,
http://www.pharming.com
Contact:
Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6
109 299 54
[HUG#1421252]
Press release (PDF): http://hugin.info/132866/R/1421252/370585.pdf
Unternehmensinformation / Kurzprofil:
Datum: 02.06.2010 - 19:35 Uhr
Sprache: Deutsch
News-ID 21894
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 278 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming provides update on outstanding shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
